Form 8-K Lucid Diagnostics Inc. For: Aug 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Cantor Fitzgerald Positive on Lucid Diagnostics Inc (LUCD) Following Earnings
August 13, 2024 2:57 PM EDTCantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).
The analyst comments "We reiterate our Overweight rating and 12-month price target of $3.00 on Lucid Diagnostics' (LUCD) shares following the company reporting 2Q24 operating results and providing... More
Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
August 12, 2024 4:47 PM EDTNeedham analyst Mike Matson reiterated a Buy rating and $2.50 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).
The analyst comments "In 2Q24, EsoGuard test volume grew 30% sequentially and 43% Y/Y to 3,147. LUCD missed consensus revenue in 2Q24 and we note that LUCD has... More
